US › Healthcare

Galectin Therapeutics Inc (GALT)

US · Healthcare · Biotechnology

$2.98-1.49%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-5.0M
Profit YoY
+47.6%
EPS
$-0.08
EPS estimate
$-0.06

EPS came in at -0.08 against a street estimate of -0.06 — a miss of 33.3%.

Key statistics

Market cap
$199.5M
Forward P/E
4.5
P/B
207.70
Book value
$-2.01
EPS (TTM)
$-0.41
52-week high
$7.13
52-week low
$2.03
50-day MA
$3.42
200-day MA
$3.65
Beta
0.35

Analyst view

Analysts rate Galectin Therapeutics Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $11.00.

Shareholding

Insiders
29.09%
Institutions
21.77%

Largest institutional holders

FundStake
Vanguard Group Inc3.48%
Vanguard Capital Management, LLC2.99%
Marshall Wace Asset Management Ltd1.85%
Advisor Group Holdings, Inc.1.70%
BlackRock Inc1.21%
Millennium Management LLC1.21%
Sontag Advisory LLC1.10%
Geode Capital Management, LLC0.93%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Galectin Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.